1.      Кутырина И.М. [и др.] Роль ремоделирования крупных сосудов в развитии гипертрофии левого желудочка на додиализной стадии хронической почечной недостаточности//Тер. арх., 2008. Т. 6. С.37-41.

2.      Мухин Н.А. [и др.]. Кардиоренальный синдром при ишемической болезни почек (атеросклеротической реноваскулярной гипертонии)//Тер. арх. 2008. Т.6. С.30-38.

3.        Родионов Р.Н., Лентц С.Р. Современные представления о гипергомоцистеинемии как факторе риска сердечно-сосудистых заболеваний//Артериальная гипертензия, 2008. Т.14. № 1. С. 110-115.

4.    Bhatia S., Shukla R., Venkata Madhu S. et al. Antioxidant status, lip peroxidation and nitric oxide end products in patients of type 2 diabetiс mellitus with nephropathy//Clin.Biochem., 2004; 36: 557-562.

5.      Clarke R., Armitage J., Levington S. et al. Homocysteinelowring trials for prevention of vascular disease: protocol for collaborative meta-analysis//Clin. Chem. Lab. Med. 2007, 45(12): 1575-1581.

6.    Dursun B., Dursun E., Suleymanlar G. et al. Carotid artery intima-media thickness corellates with oxidative stress in chrjnic haemodialysis patients with accelerated atherosclerosis//Nephrol. Dial. Transplant. 2008; 23(5):1697-1703.

7.    Jamison R.I., Hartigan P., Kaufman J.S. еt al. Effect of homocystein lowering on mortality and vascular disease in advanced chronic kidney disease and end-stage renal disease//Jama. 2007; 298(10): 1163-1170.

8.         Johnson F., Giulivi C. Superoxide dismutases and their impact upon human health//Mol. Aspects. Med. 2005; 26: 340-352.

9.    Kalinina N., Agrotis A., Tararak E. et al. Cytochrome b558-dependent NAD(P)H oxidase-phox units in smooth muscle and macrophages of atherosclerotic lesions//Arterioscler.Thromb.Vasс. Biol., 2002; 22: 2037-2043.

10.  Redon J., Cea-Calvo L., Lozano J.V. et al. Kidney function and cardiovascular disease in the hypertensive population: the ERIC-HTA study//J. Hypertens., 2006; 24: 663-669.

11.  Sardenberg C., Suassuna P., Watanabe R. et al. Balance between cytokine production by peripheral blood mononuclear cells and reactive oxygen species production by monocytes in patients with chronic kidney disease//Ren. Fail., 2004; 26: 673-681.

12.  Schiffrin E.I., Lipman M.I., Mann J.F. Chronic kidney disease: effects on the cardiovascular system//Circulation, 2007; 116 (1): 95-99.

13.  Siems W., Quast S., Carluccio F. Oxidative stress in chronic renal failure as a cardiovascular risk factor. In; Hampl H.(ed) Cardio renal anemia syndrome//Berlin: Dustri-Verlag; 2004. 16-26.

14.  Stocker R., Keaney J.F.Jr. Role of oxidative modifications in atherosclerosis//Physiol. Rev., 2004; 84: 1381-1478.

15.  Vanholder R., Massy Z., Argiles A. et al. Chronic kidney disease as cause of cardiovascular morbidity and mortality//Nephrol. Dial. Transplant., 2005; 20: 1048-1056.

16.  Vaziri N.D. Oxidative stress in uremia: nature, mechanisms, and potential consequences//Semin. Nephrol., 2004; 24: 469-473.

17.  Yilmaz M.I.,  Saglam M., Caglar K. et al. The determinants of  endothelial dysfunction in CKD: oxidative stress and asymmetric dimethylarginine//Am. J. Kidney Dis., 2006; 47: 42-50.

18.  Wang X., Qin X., Demirtas H. et al. Efficacy of folic acid supplementation in stroke prevention: a meta-analysis. NADPH oxidase-dependent superoxide production is associated with carotid intima-media thickness in subjects free of clinical atherosclerotic disease//Arterioscler. Thromb. Vasс. Biol., 2005; 25: 1452-145.